Endocannabinoids and liver disease. I. Endocannabinoids and their receptors in the liver.

Abstract

Cannabinoid receptors (CB1 and CB2) and their endogenous ligands (endocannabinoids) have recently emerged as novel mediators of liver diseases. Endogenous activation of CB1 receptors promotes nonalcoholic fatty liver disease (NAFLD) and progression of liver fibrosis associated with chronic liver injury; in addition, CB1 receptors contribute to the… (More)

Topics

Cite this paper

@article{Mallat2008EndocannabinoidsAL, title={Endocannabinoids and liver disease. I. Endocannabinoids and their receptors in the liver.}, author={Arianne Mallat and Sophie Lotersztajn}, journal={American journal of physiology. Gastrointestinal and liver physiology}, year={2008}, volume={294 1}, pages={G9-G12} }